Literature DB >> 22686342

Dissolution testing of oral modified-release dosage forms.

Grzegorz Garbacz1, Sandra Klein.   

Abstract

OBJECTIVES: The in-vivo performance of oral modified-release dosage forms is determined by the interplay of various physiological- and dosage-form-derived parameters. Thus it is often a challenge to predict the in-vivo drug-release behaviour from modified-release dosage forms based solely on in-vitro release rates. KEY
FINDINGS: For a long time the most common procedure to obtain in-vitro/in-vivo correlations for modified-release formulations was to apply test conditions typically used for quality control on a retrospective basis. Such so-called 'compendial approaches' are typically not biorelevant with respect to volumes, composition and physicochemical properties of the test media and also do not take into consideration the mechanical and hydrodynamic forces that may influence dosage-form behaviour during passage through the gastrointestinal tract.
SUMMARY: This review provides an overview of physiological conditions relevant to in-vivo drug release and of dissolution models which, based on current scientific findings on human gastrointestinal physiology, have been developed to enable a better prediction of the in-vivo performance of oral MR dosage forms.
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22686342     DOI: 10.1111/j.2042-7158.2012.01477.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.

Authors:  J D Gomez-Mantilla; U F Schaefer; V G Casabo; T Lehr; C M Lehr
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

2.  Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions.

Authors:  Grzegorz Garbacz; Anna Kandzi; Mirko Koziolek; Jarosław Mazgalski; Werner Weitschies
Journal:  AAPS PharmSciTech       Date:  2013-12-03       Impact factor: 3.246

Review 3.  Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.

Authors:  Min Li; Sanna Sander; John Duan; Susan Rosencrance; Sarah Pope Miksinski; Lawrence Yu; Paul Seo; Bhagwant Rege
Journal:  AAPS J       Date:  2016-09-20       Impact factor: 4.009

4.  Colonic Delivery of α-Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagon-Like Peptide-1 Secretion and Inhibits Food Intake in Mice.

Authors:  Remi Kamakura; Ghulam Shere Raza; Ermei Mäkilä; Joakim Riikonen; Miia Kovalainen; Yoichi Ueta; Vesa-Pekka Lehto; Jarno Salonen; Karl-Heinz Herzig
Journal:  Mol Nutr Food Res       Date:  2021-12-19       Impact factor: 6.575

5.  Development of a Surface Coating Technique with Predictive Value for Bead Coating in the Manufacturing of Amorphous Solid Dispersions.

Authors:  Eline Boel; Piyush Panini; Guy Van den Mooter
Journal:  Pharmaceutics       Date:  2020-09-15       Impact factor: 6.321

6.  IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress.

Authors:  Valentyn Mohylyuk; Seyedreza Goldoozian; Gavin P Andrews; Andriy Dashevskiy
Journal:  Pharm Res       Date:  2020-10-22       Impact factor: 4.200

7.  Gel Strength of Hydrophilic Matrix Tablets in Terms of In Vitro Robustness.

Authors:  Seyedreza Goldoozian; Valentyn Mohylyuk; Andriy Dashevskiy; Roland Bodmeier
Journal:  Pharm Res       Date:  2021-06-21       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.